PDCD1 and neoplasm: found that tumor‐infiltrating DCs producing interleukin (IL)‐12 are crucial for robust anti‐tumor responses, with T cell‐DC crosstalk, mediated by IFN‐γ and IL‐12, being vital for the success of anti‐PD‐1 therapy.[169] In addition to cDC1, cDC2 is also involved in ICI therapies.